Product
Sotrovimab
Aliases
Sotrovimab (Gen2), VIR-7831
Name
Sotrovimab
INN Name
sotrovimab
FDA Approved
Yes
12 clinical trials
1 organization
4 indications
1 document
Indication
COVID-19Indication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Malignant Solid NeoplasmIndication
SARSClinical trial
An Open-label, Non-comparator, Multicenter Study to Describe the Pharmacokinetics (PK), Pharmacodynamics (PD; Viral Load) and Safety Following a Single Intravenous or Intramuscular Dose of Sotrovimab in Pediatric Participants With Mild to Moderate COVID-19 at High Risk of Disease ProgressionStatus: Terminated, Estimated PCD: 2023-06-14
Clinical trial
A Phase 3 Randomized, Multi-center, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Monoclonal Antibody VIR-7831 (Sotrovimab) Given Intramuscularly Versus Intravenously for the Treatment of Mild/Moderate Coronavirus Disease 2019 (COVID-19) in High-risk Non-hospitalized Patients; Safety Substudy Assessing the Safety and Tolerability of Single Ascending Dose Monoclonal Antibody VIR-7831Status: Terminated, Estimated PCD: 2022-07-19
Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Participants With Mild to Moderate Coronavirus Disease 2019 (COVID-19)Status: Completed, Estimated PCD: 2021-08-20
Clinical trial
Prospective Cohort Study to Monitor the Emergence of SARS-CoV-2 Spike Viral Variants in Immunocompromised Non-hospitalized Patients Exposed to Sotrovimab in Great Britain: LUNAR StudyStatus: Recruiting, Estimated PCD: 2023-07-20
Clinical trial
Adaptive, Randomized, Non-inferiority Trial on the Use of Monoclonal Antibodies or Antivirals in Outpatients With Mild or Moderate COVID-19Status: Completed, Estimated PCD: 2023-10-29
Clinical trial
PROphylaxis for paTiEnts at Risk of COVID-19 infecTionStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Pharmacokinetics of a SARS-CoV-2 Monoclonal Antibody in Hematopoietic Stem Cell Transplant Recipients (COVIDMAB)Status: Terminated, Estimated PCD: 2022-10-18
Clinical trial
The UPMC OPtimizing Treatment and Impact of Monocolonal antIbodieS Through Evaluation for COVID-19 TrialStatus: Terminated, Estimated PCD: 2022-06-16
Clinical trial
Randomised Evaluation of COVID-19 TherapyStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 Infection in Immunocompromised Individuals With Impaired SARS-CoV-2 Humoral ImmunityStatus: Active (not recruiting), Estimated PCD: 2023-04-01
Clinical trial
Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Status: Recruiting, Estimated PCD: 2027-01-01
Document
DailyMed Label: SotrovimabOrganization
GlaxoSmithKline LLC